Vertex’s executive chairman: Here’s how we got our drug-trial success rate over 70% when the industry’s is 10% to 20%



[

Jeffrey Leiden, M.D., Ph.D., is executive chairman of Vertex Pharmaceuticals. He is a physician and scientist who has dedicated his career to improving the lives of people with serious diseases. He previously served as Vertex’s president, chief executive officer and chairman from 2012 through March 2020, and has been a member of Vertex’s board since July 2009. Under his leadership, Vertex delivered the first and only medicines to treat the underlying cause of cystic fibrosis for patients with certain forms of the disease, including Kalydeco, Orkambi and Trikafta.

Dr. Leiden serves as lead independent director of Massachusetts Mutual Life Insurance Company, chairman of Odyssey Therapeutics and chairman of Casana. He is also a member of the MIT CEO Advisory Board and a director of the Massachusetts Competitive Partnership, and serves on the Massachusetts Governor’s Digital Healthcare Council, Governor’s Task Force on Artificial Intelligence and Governor’s STEM Advisory Council. Dr. Leiden received his M.D., Ph.D. and B.A. degrees from the University of Chicago.

https://fortune.com/img-assets/wp-content/uploads/2026/11/jeffrey-leiden_6ea868.jpg?resize=1200,600
https://fortune.com/2026/11/22/vertex-leiden-rd-success-rate-fewer-smarter-bets-innovation/


Jeffrey Leiden

Latest articles

spot_imgspot_img

Related articles

Leave a reply

Please enter your comment!
Please enter your name here

spot_imgspot_img